Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward...

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• K-Ras and N-Ras mutations are prevalent in human cancers, making them key therapeutic targets.
• Inhibiting Ras protein membrane association is a strategy to block their oncogenic function.
• Previous attempts to inhibit Ras function via prenylation inhibition faced challenges due to alternative prenylation pathways.

Purpose of the Study:

• To review strategies for inhibiting K-Ras and N-Ras function by targeting their membrane association.
• To evaluate the efficacy and limitations of prenylation inhibitors (FTase and GGTase-I inhibitors).
• To discuss emerging approaches targeting postprenylation events and K-Ras/PDE-δ interactions.

Main Methods:

• Review of early prenylation inhibition strategies, including dual specificity inhibitors (DPIs).
• Examination of postprenylation inhibition approaches, such as ICMT inhibitors.
• Discussion of recent findings on compounds inhibiting K-Ras and PDE-δ interaction.

Main Results:

• Inhibition of farnesylation alone was insufficient due to alternative prenylation.
• Combined FTase and GGTase-I inhibition showed potential but faced challenges with drug concentration and toxicity.
• Postprenylation inhibitors and compounds targeting K-Ras/PDE-δ interaction represent newer therapeutic avenues.

Conclusions:

• Targeting Ras membrane association remains a viable anticancer strategy.
• Overcoming dose-limiting toxicities and achieving effective drug concentrations are critical for prenylation inhibitors.
• Novel approaches targeting postprenylation modifications and protein-protein interactions offer promising alternatives for Ras-driven cancers.